Search results
Showing 8956 to 8970 of 9128 results
To mark Time to Talk Day (February 2) we spoke with Catherine Ruane, who acted as a carer for her father and sister, who both lived with depression.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
NICE collaboration on streamlined licensing and patient access process for new medicines
Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
NICE's flexibility in evaluation of new health tech and fairer patient access
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.
NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials
James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.
Towards a new partnership – NICE and the voluntary and community sector
Victoria Thomas gives details of NICE’s new voluntary and community sector forum.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
NICE recommends 'game changing' histology independent cancer drug
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).
NICE recommends innovative treatment for severe blood disorder for NHS use
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
More than 1,000 people each year will benefit from NICE's recommendation.
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.
AI skin cancer detection system gets green light for conditional NHS use
An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected.